Luit Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 23 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets 19.50%
About Luit Bio-Tech
Luit Bio-Tech Private Limited (LBPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 December 2001 and has a history of 23 years and one month. Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mukut Deka, Geetanjali Deka, and Sisir Deka serve as directors at the Company.
Company Details
-
Location
Kamrup, Assam, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U01117AS2001PTC006700
-
Company No.
006700
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Dec 2001
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Luit Bio-Tech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sisir Deka
|
Director | 20-Jan-2011 | Current |
|
Mukut Deka
|
Director | 11-Dec-2001 | Current |
|
Geetanjali Deka
|
Director | 11-Dec-2001 | Current |
Financial Performance of Luit Bio-Tech.
Luit Bio-Tech Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Luit Bio-Tech?
In 2020, Luit Bio-Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sankardev Coke Products LimitedMukut Deka and Geetanjali Deka are mutual person
-
Luit Coal Products Private Limited
Mukut Deka and Geetanjali Deka are mutual person
-
Radha Coke Products Private Limited
Mukut Deka and Geetanjali Deka are mutual person
-
Luit Refractories Private Limited
Mukut Deka and Geetanjali Deka are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Luit Bio-Tech?
Unlock and access historical data on people associated with Luit Bio-Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Luit Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Luit Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.